Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells|
Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells consist of a defined proportion of CD4 and CD8 positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domain and a truncated human epidermal growth factor receptor (EGFRt), which has potential cytotoxic activity against CD19-expressing tumor cells (NCI Thesaurus).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells||0||1|
|Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B||Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells Iomab-B||0||1|